Fabio Malavasi
Fabio Malavasi
affiliation: Università di Torino
research area(s): Experimental Medicine, Genetics And Genomics
Course: Biomedical Sciences and Human Oncology
University/Istitution: Università di Torino
1962-67: Attended the Scientific Lyceum in Ferrara, Italy (Diploma).
1967-73: Attended the Medical School, University of Ferrara, Italy. Graduated with full score (M.D.)
1974: National Medical Board Exam (National License).

1972: Visiting Medical Student, University of Chicago Medical School, Chicago, IL.
1974-75: Medical Assistant, Department of Nuclear Medicine, "St. Anna" Hospital,
Ferrara, Italy.
1975-76: M.D. Lieutenent, Italian Army Medical Corp.
1977: Assistant Professor, Institute of Medical Genetics, University of Torino Medical School.
1978-79: Visiting Assistant Professor, Department of Medical Genetics, Mount Sinai School of Medicine, New York, N.Y.
1979: Visiting Scientist, Basel Institute for Immunology, Basel, Switzerland.
1982: Visiting Scientist, Sloan-Kettering Cancer Center, New York, N.Y.
1982: Associate Professor of Cell Biology, University of Torino Medical School, Italy.
1985: Visiting Scientist, Lab of Cellular and Molecular Biology, Beth Israel Hospital, New York, N.Y.
1994: Professor of Cell Biology, University of Ancona Medical School.
1997-2000: Director, Institute of Biology and Genetics, University of Ancona Medical School, Italy
2000-today: Professor of Medical Genetics, University of Torino Medical School, Torino, Italy.

- Analysis of cell surface differentiation molecules expressed by human leukocytes in health and tumor conditions and during organ transplantation.
- Analysis of ectoenzyme network in positive and negative regulations of effector activities of human leukocyte subsets.
- Analysis of tumor antigens or tumor-associated molecules as targets for antibody-mediated interventions.
- Member of the Board of National Experts on Biomedical Science, Italian Ministry of Public Health, 2001- 2003.
- Councillors Board, The Human Leukocyte Differentiation Antigens/HCDM, 2005 - today.
328) T. Vaisitti, S. Aydin, D. Rossi, F. Cottino, L. Bergui, G. D"Arena, L. Bonello, A. L. Horenstein, P. Brennan, C. Pepper, G. Gaidano, F. Malavasi and S. Deaglio
CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.
Leukemia: 1-12, 2010 (IF 8.296)

329) S. Deaglio, S. Aydin, MM. Grand, T. Vaisitti, L. Bergui, G. D"Arena, G. Chiorino, F. Malavasi
CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells.
Molecular Medicine: 16: 87-91, 2010 (IF 5.020)

331) E. Zumaquero, P. Muñoz, M. Cobo, G. Lucena, E. J. Pavón, A. Martín, P. Navarro, A. García-Pérez, A. Ariza-Veguillas, F. Malavasi and J. Sancho
Exosomes from human lymphoblastoid B cells express enzymatically active
CD38 that is associated with signaling complexes containing CD81, HSC-70 and lyn
Experimental Cell Research 316: 2692-2706, 2010 (IF 3.589)

332) F. Malavasi, S. Deaglio, G. Zaccarello, A. L. Horenstein, A. Chillemi, V. Audrito, S. Serra, M. Gandione, A. Zitella and A. Tizzani
The hidden life of NAD+-consuming ectoenzymes in the endocrine system
Journal of Molecular Endocrinology 45: 183-191,2010 (IF 3.221)

333) S. Deaglio, T. Vaisitti, A. Zucchetto, V. Gattei and F. Malavasi
CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells.
Seminars in Cancer Biology 20: 416-423, 2010 (IF 6.918)

334) S. Rasi, V. Spina, A. Bruscaggin, T. Vaisitti, C. Tripodo, F. Forconi, L. Depaolo, M. Fangazio, E. Sozzi, E. Cencini, L. Laurenti, R. Marasca, C. Visco, ZY Xu-Monette, V. Gattei, KH Young, F. Malavasi, S. Deaglio, D. Rossi and G. Gaidano.
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.
British Journal of Haematology 1111: 1365-2141, 2010 (IF 4.597)

335) A. Pezzolo, F. Parodi, D. Marimpietri, L. Raffaghello, C. Cocco, A. Pistorio, M. Mosconi, C. Gambini, M. Cilli, S. Deaglio, F. Malavasi, and V. Pistoia.
OCT-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells.
Cell Research (In press, 2010) (IF 8.151)

336) J. Congleton, H. Jiang, F. Malavasi, H. Lin
ATRA-induced HL-60 myeloid leukemia cell differentiation depends on the CD38 cytosolic tail needed for membrane localization, but CD38 enzymatic activity is unnecessary
Experimental Cell Research 317: 910-919, 2011 (IF 3.589)

337) I. Saborit-Villarroya, T. Vaisitti, D. Rossi, G. D"Arena G. Gaidano F. Malavasi and S. Deaglio
EA2 is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia.
Leukemia 25: 479-488, 2011 (IF 8.296)

338) A. Corcione, S. Deaglio, F. Malavasi
A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia (CLL) cells and tumor microenvironment.
Leukemia (In press, 2011) (IF 8.296)

339) S. Sandini, R. La Valle, S. Deaglio, F. Malavasi, A. Cassone, F. De Bernardis.
A highly immunogenic recombinant and truncated protein of the
secreted aspartic proteases family (rSap2t) of Candida albicans as a
mucosal anticandidal vaccine.
FEMS Immunology & Medical Microbiology (In press, 2011) (IF 2.335)
340) R.P. Ebstein, D. Mankuta, N. Yirmiya and F. Malavasi.
Are retinoids potential therapeutic agents in disorders of social cognition including autism?
FEBS Letters (In press, 2011) (IF 3.541)

341) F. Malavasi
CD38 and retinoids: a step toward a cure.
Journal of Leukocyte Biology (In press, 2011) (IF 4.403)

342) M. Riebold, D. Mankuta, E. Lerer, S. Israel, S. Zhong, L. Nemanov, M.V. Monakhov, S. Levi, N. Yirmiya, M. Yaari, F. Malavasi and R. Ebstein.
All-trans-Retinoic-Acid (ATRA) upregulates reduced CD38 transcription in lymphoblastoid cell lines from autism spectrum disorder.
Molecular Medicine (In press, 2011) (IF 5.020)

343) E. Ferretti, M. Bertolotto, S. Deaglio, C. Tripodo, D. Ribatti, V. Audrito, F. Blengio, S. Matis, S. Zupo, D. Rossi, L. Ottonello, G. Gaidano, F. Malavasi, V. Pistoia and A. Corcione.
A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment.
Leukemia (In press, 2011) (IF 8.296)

344) V. Audrito, T. Vaisitti, D. Rossi, D. Gottardi, G. D"Arena, L. Laurenti, G. Gaidano, F. Malavasi and S. Deaglio.
Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.
Cancer Research (In press, 2011) (IF 7.543)

345) S. Deaglio, T. Vaisitti, S. Serra, V. Audrito, C. Bologna, G. D"Arena, L. Laurenti, D. Gottardi and F. Malavasi.
CD38 in chronic-lymphocytic leukemia: from bench to bedside?
Mini Reviews on Medicinal Chemistry (In press, 2011) (IF 1.642)

346) F. Malavasi, S. Deaglio, R. Damle, G. Cutrona, M. Ferrarini, N. Chiorazzi.
CD38 and chronic lymphocytic leukemia: a decade later.
Blood (In press, 2011) (IF 10.555)

Project Title:
Immunolocalization of human tumors.
The aim of our research Project is to exploit miRNAs as drugs or targets in innovative therapeutic strategies for Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) based on biological driven hypothesis, novel in vitro and in vivo preclinical models and delivery nanotechnologies.
The experimental design includes production and characterization of monoclonal antibodies for target identification, scale-up of the production of clinical grade antibodies, bioreagent development, validation in in vitro appropriate cellular system and preclinical studies.

Project Title:
Generation of humanized and human antibodies for in vivo diagnosis and therapy